US equities |
TSLA $391.62 ▲+5.21% MU $903.70 ▲+2.98% NVDA $216.00 ▲+2.39% META $630.56 ▼-1.88% SPCX $146.90 ▼-0.40% AAPL $343.91 ▼-1.10% MSFT $532.60 ▲+1.54% INTC $90.47 ▲+4.04%
FinancialContent

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.7084 -0.0313 (-4.23%)
Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
News headline image
Ocugen to Present at April 2026 Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
From Ocugen
Via GlobeNewswire
Ocugen Inc (NASDAQ:OCGN) Stock Drops 7% on Q4 Revenue Miss, Highlights Clinical Pipeline ↗
Via Chartmill
News headline image
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
From Ocugen
Via GlobeNewswire
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data ↗
Canaccord has a $12 price target on the stock, representing a potential upside of about 415% from the stock’s closing price on Monday. 
Via Stocktwits
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Ocugen (OCGN) Q4 2025 Earnings Call Transcript ↗
Ocugen (OCGN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET 
From Ocugen
Via GlobeNewswire
News headline image
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
News headline image
Why Did OCGN Stock Rise Today? ↗
Ocugen said that it intends to start seeking the approval of the FDA for its experimental therapy OCU400 starting this year. 
Via Stocktwits
News headline image
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Stock Is Surging Today: What&#39;s Driving The Action? ↗
Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment. 
Via Benzinga
News headline image
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
From Ocugen
Via GlobeNewswire
News headline image
OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder ↗
Stargardt disease is a form of inherited macular degeneration, affecting more than 100,000 people in the U.S. and Europe combined. 
Via Stocktwits
News headline image
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
News headline image
Ocugen (OCGN) Q3 2025 Earnings Call Transcript ↗
Ocugen (OCGN) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
OCUGEN INC (NASDAQ:OCGN) Reports Mixed Q3 2025 Results Amid Clinical Pipeline Progress ↗
Ocugen reports Q3 2025 results with a major revenue beat and updates on its late-stage gene therapy pipeline for blindness diseases. 
Via Chartmill
News headline image
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET 
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >